The levels of H11/HspB8 DNA methylation in human melanoma tissues and xenografts are a critical molecular marker for 5-Aza-2′-deoxycytidine therapy

Cancer Investigation

Volumn 29, Issue 6, 2011, Pages 383-395

  Smith, Cynthia C ^a   Li, Baiquan ^a   Liu, Juan ^a   Lee, Kie Sok ^a   Aurelian, Laure ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Cutaneous melanoma; Gene expression; Molecular biology; Prognosis and response predictions; Therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN B8; MOLECULAR MARKER; PHOSPHATIDYLINOSITOL 3 KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CANCER TISSUE; CELL DEATH; CONTROLLED STUDY; DNA METHYLATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MELANOMA; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; XENOGRAFT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; CELL CYCLE; DNA METHYLATION; FEMALE; HEAT-SHOCK PROTEINS; HUMANS; MELANOCYTES; MELANOMA; MICE; MICE, INBRED BALB C; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79958192790     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2011.584588     Document Type: Article

References (58)

1. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br J Dermatol 2004;150:179-185. (Pubitemid 38352453)
2. Gershenwald JE, Soong SJ, Balch CM. On behalf of the American Joint Committee on Cancer (AJCC)Melanoma Staging Committee. 2010 TNM Staging System for Cutaneous Melanoma and Beyond. Ann Surg Oncol 2010;6:1475-1477.
3. Ghosh P, Chin L. Genetics and genomics of melanoma. Expert Rev Dermatol 2009;4:131-143.
4. Palmieri G, Capone M, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, SiniMC, Palla M,Mozzillo N, Ascierto PA.Main roads to melanoma. J Transl Med 2009;7:86.
5. Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'DorisioMS, HeldWA,Cavenee WK, Plass C. Aberrant CpG-island methylation has non-random and tumor specific patterns. Nature Genet 2000;24:132-138. (Pubitemid 30094712)
6. Jones PA, Laird PW. Cancer epigenetics comes of age. Nature Genet 1999;21:163-167. (Pubitemid 29070360)
7. Howell P, Liu S, Ren S, Behlen C, FodstadO, Riker AI. Epigenetics in human melanoma. Cancer Control 2009;16:200-218.
8. Furuta J, Umebayashi Y, Miyamato K, Kikuchi K, Otsuka F, Sugimura T, Ushijima T. Promoter methylation profiling of 30 genes in human malignant melanoma. Cancer Sci 2004;95:962-968. (Pubitemid 40089588)
9. Gallagher WM, Bergin OE, Rafferty M, Kelly ZD, Nolan IM, Fox EJ, Culhane AC, McArdle L, Fraga MF, Hughes L, Currid CA, O'Mahony F, Byrne A, Murphy AA, Moss C, McDonnell S, Stallings RL, Plumb JA, Esteller M, Brown R,Dervan PA, EastyDJ. Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis 2005;26:1856-1867. (Pubitemid 41631258)
10. Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, Nelson B, Bosenberg M. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res 2006;66:11187-11193. (Pubitemid 46009946)
11. Rothhammer T, Bosserhoff AK. Epigenetic events in malignant melanoma. Pigment Cell Res 2007;20:92-111. (Pubitemid 46439524)
12. Liu S, Ren S, Howell P, Fodstad O, Riker AI. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling. Pigment Cell Melanoma Res 2008;21:545-558.
13. Halaban R, Krauthammer M, Pelizzola M, Cheng E, Kovacs D, SznolM, Ariyan S,NarayanD, Bacchiocchi A,Molinaro A, Kluger Y, Deng M, Tran N, ZhangW, Picardo M, Enghild JJ. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications. PLoS One 2009;4:e456.
14. Smith CC, Yu YX, KulkaM, Aurelian L. A novel human gene similar to the protein kinase (PK) coding domain of the large subunit of herpes simplex virus type 2 ribonucleotide reductase (ICP10) codes for a serine-threonine PK and is expressed in melanoma cells. J Biol Chem 2000;275:25690-25699.
15. Aurelian L, Smith CC, Winchurch R, Kulka M, Gyotoku T, Zaccaro L, Chrest FJ, Burnett JW. A novel gene expressed in human keratinocytes with long-term in vitro growth potential is required for cell growth. J Invest Dermatol 2001;116:286-295. (Pubitemid 32173734)
16. Yu X, Heller A, Liehr T, Smith CC, Aurelian L. Expression analysis and chromosome location of a novel gene (H11) associated with the growth of human melanoma cells. Int J Oncol 2001;18:905-911.
17. DepreC,HaseM, GaussinV,ZajacA,WangL,HittingerL,Ghaleh B, Yu X, Kudej RK, Wagner T, Sadoshima J, Vatner SF. H11 kinase is a novel mediator of cardiac hypertrophy in vivo. Circ Res 2002;91:1007-1014. (Pubitemid 35416637)
18. Depre C, Wang L, Sui X, Qiu H, Hong C, Hedhli N, Ginion A, Shah A, Pelat M, Bertrand L, Wagner T, Gaussin V, Vatner SF. H11 kinase preventsmyocardial infarction by preemptive preconditioning of the heart. Circ Res 2006;98:280-288.
19. Danan IJ, Rashed ER, Depre C. Therapeutic potential of H11 kinase for the ischemic heart. Cardiovasc Drug Rev 2007;25:14-29. (Pubitemid 46625288)
20. GoberMD, SmithCC,Ueda K, Toretsky JA,Aurelian L. Forced expression of the H11 heat shock protein can be regulated by DNA methylation and trigger apoptosis in human cells. J Biol Chem 2003;278:37600-37609.
21. GoberMD,Wales SQ, Aurelian L.Herpes simplex virus type 2 encodes a heat shock protein homologue with apoptosis regulatory functions. Front Biosci 2005;10:2788-2803. (Pubitemid 40905275)
22. Chowdary TK, Ramon B, Ramakrishna T, Raos CM. Mammalian Hsp22 is a heat inducible small heat-shock protein with chaperone-like activity. Biochem J 2004;381:379-387. (Pubitemid 38969681)
23. Li B, Smith CC, Laing JM, Liu L, Aurelian L. Overload of the heat-shock protein H11/HspB8 triggers melanoma cell apoptosis through activation of transforming growth factor-b-activated kinase 1. Oncogene 2007;26:3521-3531. (Pubitemid 46816763)
24. Danam RP, Howell SR, Remack JS, Brent TP. Heterogeneousmethylation of theO(6)-methylguanine-DNAmethyltransferase promoter in immortalized IMR90 cell lines. Int J Oncol 2001;18:1187-1193.
25. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol 2008;35:433-444. (Pubitemid 351519417)
26. Martinez-Galan J, Torres B, Del Moral R, Munoz-Gamez JA, Martin-Oliva D, Villalobos M, Nunez MI, Luna Jde D, Oliver FJ, Ruiz de Almodovar JM. Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer BiolTher 2008;7:958-965.
27. Hatterman K, Mehdorn HM, Mentlein R, Schultka S, Held- Feindt JA. Methylation-specific and SYBR-green-based quantitative polymerase chain reaction technique for O6-methylguanine DNA methyltransferase promoter methylation analysis. Anal Biochem 2008;377:62-71.
28. Ohtsubo M, Theodoras AM, Schumacher J, Roberts JM, Pagano M. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995;25:2612-2624.
29. Resnitzky D, Reed S. Different roles for cyclins D1 and E in regulation of the G1-to-S transition.Mol Cell Biol 1995;27:3463-3469.
30. He KC, Yin T, Grindley JC, Tian Q, Sato T, Tao WA, Dirsina R, Porter-Wastphal T,Hembree M, Johnson T,Wiedemann LM, Barrett TA, Hood L, Wu H, Li L. PTEN-deficient stem cells initiate intestinal polyposis. Nat Genet 2007;39:189-198. (Pubitemid 46184349)
31. Zhou F, Zhang L, Gong K, Lu G, Sheng B,Wang A, Zhao N, Zhang X, Gong Y. LEF-1 activates the transcription of E2F1. Biochem Biophys Res Comm 2008;365:149-153. (Pubitemid 350102466)
32. Amit S, Hatzubai A, Birman Y, Andersen JS, Ben-Shushan E, Mann M, Ben-Neriah Y, Alkalay I. Axin-mediated CK1 phosphorylation of beta-catenin at Ser 45: amolecular switch for theWNT pathway. Genes Dev 2002;16:1066-1076. (Pubitemid 34507196)
33. Park CS, Kim SI, Lee MS, Youn CY, Kim DJ, Jho EH, Song WK. Modulation of beta-catenin phosphorylation/degradation by cyclin-dependent kinase 2. J Biol Chem 2004;279:19592-19599. (Pubitemid 38623395)
34. Tauren S, Sanbo N, Qin Y, Browining D, Dulin NO. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase. J Biol Chem 2006;281:9971-9976. (Pubitemid 43864529)
35. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci 1995;92:12146-12150. (Pubitemid 26014027)
36. Mac A, Carpenter M, Smillie LB, Wang JH. Phosphorylation of caldesmon by p34cdc2 kinase. J Biol Chem 1991;266:19971-19975.
37. Meier F, SchittekB, BuschS,GarbeC, SmalleyK, SatyamoorthyK, Li G, Herlyn M. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 2005;10:2986-3001. (Pubitemid 40910537)
38. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501. (Pubitemid 37328931)
39. Dhawan P, Singh AB, Ellis DL, Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res 2002;62:7335-7342. (Pubitemid 36025257)
40. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L, Robertson GP. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res 2004;64:7002-7010. (Pubitemid 39331010)
41. Sinnberg T, Lasithiotakis K, Niessner H, Schittek B, Flaherty KT, Kulms D, Maczey E, Campos M, Gogel J, Garbe C, Meier F. Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide. J Invest Dermatol 2009;129:1500-1515.
42. Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally J, Verma A. Aberrant DNA methylation in malignant melanoma. Melanoma Res 2010;20:253-265.
43. Sigalotti L, Covre A, Fratta E, Paris G, Colizzi F, Rizzo A, Danielli R, Nicolay HJ, Coral S, Maio M. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med 2010;8:56.
44. Freedburg DE, Rigas SH, Russak J, Gai W, Kaplow M, Osman I, Turner F, Randerson-Moor JA, Houghton A, Busam K, Timothy BD, Bastian BC, Newton-Bishop JA, Polsky D. Frequent p16- independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst 2008;100:784-795. (Pubitemid 351809672)
45. HoonDS, SpugnardiM,Kuo C, Huang SK, MortonDL,Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004;23:4014-4022. (Pubitemid 38747930)
46. Reu FJ, Leaman DW, Maitra RR, Bae SI, Cherkassky L, Fox MW, Rempinski DR, Beaulieu N,MacLeod AR, Borden EC. Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons. Cancer Res 2006;66:2785-2793.
47. Sui X, Li D, Qiu H, Gaussin V, Depre C. Activation of the bone morphogenetic protein receptor by H11kinase/Hsp22 promotes cardiac cell growth and survival. Circ Res 2009;104:887-895.
48. Sanbe A, Daicho T, Mizutani R, Endo T, Miyauchi N, Yamauchi J, Tanonaka K, Glabe C, Tanoue A. Protective effect of geranylgeranylacetone via enhancement of HSPB8 induction in desminrelated cardiomyopathy. PLoS One 2009;4:e5351.
49. Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995;377:552-557.
50. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-684.
51. St. Clair S, Manfredi JJ. The dual specificity phosphatase Cdc25C is a direct target for transcriptional repression by the tumor suppressor p53. Cell Cycle 2006;5:709-713.
52. Prives C,Manfredi JJ. The continuing saga of p53-more sleepless nights ahead. Cell 2005;19:719-721. (Pubitemid 41316665)
53. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB, Varley JM. Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 2001;20:4621-4628. (Pubitemid 32762434)
54. Gasco M, Yulug IG, Crook T. TP53 mutations in familial breast cancer: functional aspects. Hum Mutat 2003;3:301-306. (Pubitemid 36292972)
55. Abele R, Clavel M, Dodian P, Bruntsch U, Gunderson S, Smythe J, Renard J, van Glabbeke M, Pinedo HM. The EORTC Early Clinical Trials Cooperative Group experience with 5′-aza-2′- deoxycytidine (NSC 127716) in patients with colo-rectal, head and next, renal carcinomas andmalignantmelanomas. Eur J Cancer Clin Oncol 1987;23:1921-1924. (Pubitemid 18013335)
56. Schwabe M, Lubbert M. Epigenetic lesions in malignant melanoma. Curr Pharm Biotechnol 2007;8:382-387. (Pubitemid 350268197)
57. Reu FJ, Bae SI, Cherkassky L, Leaman DW, Lindner D, Beaulieu N, MacLeod AR, Borden EC. Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA methylation. J Clin Oncol 2006;24:3771-3779. (Pubitemid 46622316)
58. Gollob JA, Schlambi CJ, Peterson BL, Richmond T,Thoreson M, Moran K, DressmanHK, Jelinek J, Issa JP. Phase I trial of sequential low-dose 5-aza-2′-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma. Clin Cancer Res 2006;12:4619-4627. (Pubitemid 44297813)